Skip to main content
. 2019 Oct 14;11(10):1559. doi: 10.3390/cancers11101559

Figure 2.

Figure 2

Representative cases of patients treated with different loco-regional treatments on oligoprogression sites while continuing systemic treatments: (a) Patient treated with strereotactic surgery on brain metastases and anti-BRAF plus anti-MEK systemic therapy; (b) patient treated with local electrochemotherapy and systemic anti-PD-1 immunotherapy.